Conditions: Type 2 Diabetes Mellitus
Keywords: MT-2412 MP-513 TA-7284 Teneligliptin Canagliflozin
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 154
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of co-administration of Canagliflozin (TA-7284) and Teneligliptin (MP-513) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Canagliflozin and have inadequate glycemic control.

Detailed description:

Arms:
arm 1: Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin. arm 2: Patients receive placebo for 24 weeks in combination with Canagliflozin.

Interventions: intervention 1: Canagliflozin intervention 2: Teneligliptin intervention 3: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: